DLG2: A Potential Drug Target and Biomarker (G1740)

Target Name: DLG2

NCBI ID: G1740

DLG2

DLG2: A Potential Drug Target and Biomarker

The development of new treatments for various diseases has led to the identification of potential drug targets. One such target is the proteinDLG2, which has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology of DLG2, its potential as a drug target, and its potential as a biomarker for disease.

Biography of DLG2

DLG2 stands for doublecortin-like growth factor 2, and it is a protein that is expressed in various tissues and cells in the body. It is a member of the TGF-β family, which is a well-known signaling pathway that regulates cell growth, differentiation, and survival. DLG2 is involved in the regulation of cell proliferation, differentiation, and survival, and it has been implicated in the development and progression of various diseases.

Potential Drug Target

DLG2 has been identified as a potential drug target due to its involvement in the regulation of cell proliferation and differentiation. It has been shown to play a role in the development of cancer, neurodegenerative diseases, and autoimmune disorders. Several studies have shown that inhibition of DLG2 can lead to the inhibition of cancer cell growth and the regression of neurodegenerative diseases. Additionally, inhibition of DLG2 has been shown to be effective in treating autoimmune disorders, such as rheumatoid arthritis and lupus.

Potential Biomarker

DLG2 has also been identified as a potential biomarker for various diseases. Its expression has been shown to be elevated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, studies have shown that the levels of DLG2 have been correlated with the severity of certain diseases, such as cancer and neurodegenerative diseases.

The Benefits of Treating with DLG2

Treating with DLG2 has been shown to have several benefits, including the inhibition of cancer cell growth and the regression of neurodegenerative diseases. Additionally, treating with DLG2 has been shown to be effective in treating autoimmune disorders, such as rheumatoid arthritis and lupus.

Conclusion

In conclusion, DLG2 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its involvement in the regulation of cell proliferation and differentiation makes it an attractive target for the development of new treatments. The inhibition of DLG2 has been shown to be effective in treating cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the potential of DLG2 as a drug target and biomarker.

Protein Name: Discs Large MAGUK Scaffold Protein 2

Functions: Required for perception of chronic pain through NMDA receptor signaling. Regulates surface expression of NMDA receptors in dorsal horn neurons of the spinal cord. Interacts with the cytoplasmic tail of NMDA receptor subunits as well as inward rectifying potassium channels. Involved in regulation of synaptic stability at cholinergic synapses. Part of the postsynaptic protein scaffold of excitatory synapses (By similarity)

The "DLG2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLG2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets